Get the latest market trends in your inbox
Stay on top of the latest market trends and economic insights with the Axios Markets newsletter. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul
Tampa-St. Petersburg news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg
Michael Mortensen via Flickr CC
Bloomberg columnist Max Nisen has an insightful take on Marathon Pharmaceuticals' $89,000 list price for its steroid for Duchenne muscular dystrophy:
By pricing the drug so aggressively at a time when President Trump and others are focused on high prices, Marathon is creating substantial political and commercial risk for itself and its peers.
What to watch: Especially since Trump latches onto the idea that other countries are pricing drugs much more cheaply than the United States, the move could put the drug industry in his crosshairs again just as they were starting to improve their relationship. It also means insurers may decide not to cover the drug since it's priced so high. Those suffering from Duchenne muscular dystrophy may switch to cheaper alternatives, too.